The five NUP214 fusion abnormalities represent only a subset of AML patients with genetic abnormalities affecting nuclear pore molecules, another important AML subset is patients with NUP98-oncofusions that generally have an adverse prognosis [19,228,229,230]. This evidence concerns the gene NUP214 and acute myeloid leukemia.